I now have comprehensive information from multiple authoritative dermatology textbooks (Andrews', Fitzpatrick's, Dermatology 2-Volume Set). Let me compose the exam answers.
a) Lipodermatosclerosis (10 Marks)
Definition
Lipodermatosclerosis (LDS), also called sclerosing panniculitis or hypodermitis sclerodermiformis, is a form of panniculitis affecting the subcutaneous fat of the lower legs, characterized by progressive inflammation and fibrosis secondary to chronic venous insufficiency.
(Andrews' Diseases of the Skin; Fitzpatrick's Dermatology)
Epidemiology
- Most common form of panniculitis
- Predominantly affects overweight women > 40 years (F:M ratio up to 12:1)
- 85% of patients have BMI > 30
- Associated comorbidities: hypertension, diabetes mellitus, prior DVT/cellulitis, thyroid disease, obstructive sleep apnea
Etiopathogenesis
The underlying cause is chronic venous insufficiency (varicosities, DVT, superficial thrombophlebitis). Pathogenic mechanisms include:
- Elevated hydrostatic pressure → increased vascular permeability → extravascular fibrin deposition
- Microthrombi formation; defects in fibrinolysis (protein C/S abnormalities)
- Hypoxia → macrophage infiltration, inflammatory cytokines → fibrosis
- Upregulation of TGF-β1 → collagen I/III stimulation → fibrosis
- Occasionally drug-induced (gemcitabine, pemetrexed)
Clinical Features
Acute Phase
- Painful, poorly demarcated, cellulitis-like red-to-purple indurated plaques on the lower medial leg/anteromedial calf
- Bilateral in many cases
- DDx: cellulitis, thrombophlebitis, erythema nodosum, inflammatory morphea
Chronic Phase
- Woody, sclerotic induration with hyperpigmentation in a stocking distribution
- Classic "inverted champagne bottle" or "bowling pin" deformity — calves taper at the ankles from fibrosis of the subcutaneous fat
- Skin is tight, tethered, and depressed
Histopathology
Features vary with disease stage:
- Dermis: Stasis changes — nodular proliferation of thick-walled vessels, hemosiderin deposition, fibrosis, lymphohistiocytic infiltrate
- Early lesions: Ischemic necrosis at the center of fat lobules → "ghost cells" (pale cell walls with no nuclei); thickened septa; sparse lymphocytic septal infiltrate
- Evolving lesions: Mixed infiltrate (lymphocytes, plasma cells, macrophages); foamy histiocytes around fat necrosis
- Lipomembranous fat necrosis: Pathognomonic small fat microcysts with feathery eosinophilic remnants of adipocytes lining the cyst cavity ("frost on a window")
- Late lesions: Microcysts collapse → replaced by dense fibrosis; lobular panniculitis without vasculitis
Diagnosis
- Primarily clinical
- Doppler/duplex ultrasound to confirm venous insufficiency
- MRI preferred over biopsy to avoid poor wound healing
- If biopsy needed: take from the most proximal edge of involvement
- Lab: rarely required; may reveal genetic mutations in the fibrinolytic system
Treatment
| Modality | Details |
|---|
| Compression stockings (graded) | First-line; with limb elevation |
| Pentoxifylline | Enhances fibrinolysis and microcirculation |
| Hydroxychloroquine | May be added to pentoxifylline |
| Anabolic steroids (stanozolol/oxandrolone) | Enhance fibrinolytic capacity; avoid in women of childbearing age (virilizing); risk of hepatitis |
| Ultrasound therapy | Useful adjunct |
| Platelet-rich plasma (intralesional) | Reported benefit in refractory cases |
| Surgical | Treatment of varicosities/incompetent perforators → dramatic improvement |
⚠ Fibrosis may be irreversible. Rare complication: angiosarcoma in the setting of postphlebitic LDS.
(Andrews' Diseases of the Skin, p. 568; Fitzpatrick's Dermatology)
b) Sézary Syndrome (10 Marks)
Definition
Sézary syndrome (SS) is a leukemic form of cutaneous T-cell lymphoma (CTCL) defined by the classic triad of:
- Generalized erythroderma
- Generalized lymphadenopathy
- Circulating neoplastic T cells (Sézary cells) with cerebriform nuclei in peripheral blood, skin, and lymph nodes
(Dermatology 2-Volume Set 5e; Fitzpatrick's; Andrews')
Epidemiology
- Accounts for < 5% of all CTCL (some sources cite ~3%)
- Occurs exclusively in adults; slightly more common in males
- Unlike MF (which may progress to SS), most SS patients present with erythroderma from onset
- Poor prognosis: 5-year overall survival only 24–43%
Pathogenesis
- Neoplastic CD4+ T cells (helper T cells); origin: central memory or other T cell subsets
- Th2 phenotype → elevated IgE, eosinophilia, reduced delayed-type hypersensitivity
- Resistance to Fas-ligand and TNF-related apoptosis
- Chromosomal aberrations common; high degree of single-cell heterogeneity
- HTLV-1 has not been conclusively implicated
Clinical Features
| Feature | Details |
|---|
| Erythroderma | Generalized, fiery red, intensely pruritic; marked exfoliation, edema, lichenification |
| Leonine facies | Diffuse facial erythema and infiltration |
| Eyelid edema and ectropion | |
| Diffuse alopecia | |
| Palmoplantar hyperkeratosis | Fissuring of palms and soles |
| Onychodystrophy | Dystrophic nails |
| Lymphadenopathy | Cervical, axillary, inguinal — superficial |
| Leukocytosis | Up to 30,000 cells/mm³ |
| Vitiligo-like lesions | Especially on lower legs (some cases) |
| Severe pruritus and burning | Episodes of chills |
Diagnostic Criteria (ISCL/EORTC)
Diagnosis requires erythroderma + positive T-cell clone in peripheral blood + at least one B2 criterion:
- Absolute Sézary cell count ≥ 1000 cells/µL
- CD4/CD8 ratio > 10 in peripheral blood
- CD4+CD7⁻ cells ≥ 40% or CD4+CD26⁻ cells ≥ 30%
Sézary cells: Large mononuclear cells with lobulated, cerebriform (cerebroid) nuclei — first described by Sézary in 1938. They are T cells with the immunophenotype: CD3+, CD4+, CD8−, CD7−, CD26−, and express PD-1 (CD279) in almost all cases.
Laboratory & Histopathology
- Histology: May mimic MF — bandlike/epidermotropic dermal infiltrate with Pautrier microabscesses; often nonspecific/spongiotic in up to 1/3 of biopsies
- Bone marrow: May be involved (often sparse, interstitial)
- Lymph nodes: Dense monotonous Sézary cell infiltrate with effacement of normal architecture
- T-cell gene rearrangement studies: Identical clone in skin and blood — key diagnostic criterion
- Flow cytometry: CD3+/CD4+/CD7−/CD26− expanded population
- Novel biomarkers: PD-1, TOX, KIR3DL2 (CD158k)
- Eosinophilia and elevated IgE — from Th2 cytokines
Differential Diagnosis
Erythroderma from: psoriasis, atopic dermatitis, pityriasis rubra pilaris, drug reaction, seborrheic dermatitis, contact dermatitis, CLL, photodermatitis, idiopathic erythroderma.
Key: Demonstration of identical T-cell clone in skin and blood distinguishes SS from non-neoplastic erythroderma. Actinic reticuloid: predominant CD4−/CD8+ (inverted ratio).
Treatment
Systemic treatment is mandatory (SS is a leukemic disease):
| Modality | Details |
|---|
| Extracorporeal photopheresis (ECP) | Treatment of choice; overall response 30–80%, CR 14–25%; used alone or in combination |
| Low-dose methotrexate | ~50% response rate; median OS ~101 months; first-line systemic option |
| IFN-α | Alone or combined with PUVA; complete responses uncommon |
| PUVA/topical corticosteroids | Adjuvant skin-directed therapies |
| Total skin electron beam (TSEB) | Complete cutaneous responses; also reduces blood burden |
| Mogamulizumab (anti-CCR4 monoclonal Ab) | Second-line; most effective with blood involvement; causes mogamulizumab-associated rash (MAR) |
| Alemtuzumab (low-dose SC) | Second-line |
| Single-agent chemotherapy | Gemcitabine, liposomal doxorubicin |
| Multi-agent chemotherapy | CHOP/CHOP-like (responses short-lived) |
| Allogeneic HSCT | Potentially curative, even in advanced disease |
Prognosis
- 5-year overall survival: ~24–43% (Dermatology 5e: ~35%)
- Average survival: ~5 years (Andrews')
- Most patients die of opportunistic infections due to immunosuppression
(Dermatology 2-Volume Set 5e, p. 2585–2586; Fitzpatrick's Dermatology, p. 2113; Andrews' Diseases of the Skin)